connected people
Everyone included in the group-level summaries on this site.
VARIANT LANDSCAPE
Keep denominators, transcripts, proteins, coordinate systems, consequence, and measured mechanism separate.
WHAT EACH COUNT MEANS
Everyone included in the group-level summaries on this site.
A molecular result is recorded for 62 of 63 connected people; one molecular result remains pending. Recorded descriptions do not establish independent verification of every complete genetic result.
One sequence-defined result per person: 33 LoF/truncating and 19 single-missense results.
The 33 LoF/truncating and 19 single-missense results that can each be shown at one protein position.
ALL 63 CONNECTED PEOPLE
Bar length represents the share of the 63 connected people. It is not an effect-size or severity scale.
REFERENCE SYSTEMS
Different transcripts and protein isoforms can number the same variant differently. Keep the original transcript, protein accession, genome build, and isoform, and convert coordinates before comparing positions.
NM_018489.3 transcript
NP_060959.2 protein
Q9NR48-2 UniProt isoform
NM_001366177.2 transcript
NP_001353106.1 protein
Q9NR48-1 UniProt isoform
The references match through residue 2,034. After the insertion, convert MANE to canonical by adding 5; convert canonical positions 2,040–2,969 to MANE by subtracting 5.
Open the full reference identity →Do not apply a blanket 5-residue shift. The mapping is 1:1 through 2,034, contains a 5-residue canonical-only gap, and shifts only after that breakpoint. Verify the accession and reference residue before comparing a variant, domain, or construct.
FROM CONSEQUENCE TO MECHANISM
ASH1L haploinsufficiency is established at the gene level. Sequence consequence, predicted RNA fate, protein effect, clinical classification, and functional evidence must still be evaluated separately for an individual allele.
ClinGen supports an autosomal-dominant gene–disease relationship and sufficient haploinsufficiency evidence.
Predicted NMD, predicted escape, unresolved RNA fate, protein abundance, localization, complex assembly, and functional output are distinct states.
Measure: Transcript and exon use; allele-specific RNA; predicted NMD, predicted escape, or unresolved RNA fate; full-length and shorter protein; localization.
Do not infer: A stop, frameshift, or splice consequence does not by itself prove NMD, absence of protein, or allele-specific functional loss.
Measure: Protein abundance, folding, localization, partner binding, nucleosome engagement, catalytic control, and correction or rescue in a relevant state.
Do not infer: Missense is a sequence consequence—not a mechanism, pathogenicity class, or severity category.
Measure: RNA from an informative tissue or validated model, ideally with long-read confirmation and protein follow-up.
Do not infer: A predicted splice effect is not the same as an observed RNA consequence.
Measure: Interval and genome build, genes and elements included, phase, segregation, copy-number structure, additional findings, and tissue distribution where relevant.
Do not infer: A multigene or multi-event result cannot be forced into a single-allele position or severity ladder.